Trelaget Tablet 50Mg (1 Box = 4 Tablets)
Trelagliptin inhibits dipeptidyl-peptidase-4 (DPP-4) activity which inactivates glucagon-like peptide-1 (GLP-1)...
Trelagliptin inhibits dipeptidyl-peptidase-4 (DPP-4) activity which inactivates glucagon-like peptide-1 (GLP-1) secreted into blood from the intestine upon stimulation after oral intake of meals, trelagliptin increases the blood concentration of GLP-1 and promotes insulin secretion by the pancreas dependently on glucose concentration.
Purpose
Diabetes
Ingredients
Trelagliptin
Warnings
Acute pancreatitis has been associated with other DPP-4 inhibitors. After initiation of trelagliptin, patients is advised to be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, trelagliptin is advised to be promptly discontinued and appropriate management is advised to be initiated.
Trelagliptin is advised to not be administered to women who are or may be pregnant, unless the expected therapeutic benefit is thought to outweigh any possible risk.
During the treatment with trelagliptin, nursing is advised to be avoided if the administration of this drug is necessary for the mother.
Side Effects
Hypersensitivity : Rash and pruritus. Cardiovascular : Atrial fibrillation. Hepatic : ALT increased, AST increased and γ-GTP increased. Others : Lipase increased, amylase increased, CPK increased, urinary occult blood positive nasopharyngitis.
Storage Instructions
Store this medicine at room temperature, away from direct light and heat.
| Brand | Horizon |
| Status | Active |
Related Products
